OMER [NASD]
Omeros Corporation
Index- P/E- EPS (ttm)-3.13 Insider Own4.03% Shs Outstand62.73M Perf Week35.16%
Market Cap188.14M Forward P/E- EPS next Y-1.79 Insider Trans0.00% Shs Float60.20M Perf Month22.31%
Income-196.00M PEG- EPS next Q-0.64 Inst Own46.50% Short Float21.74% Perf Quarter-50.83%
Sales- P/S- EPS this Y-1.50% Inst Trans-5.78% Short Ratio11.81 Perf Half Y-59.34%
Book/sh-0.08 P/B- EPS next Y5.20% ROA- Target Price12.00 Perf Year-80.75%
Cash/sh2.24 P/C1.32 EPS next 5Y- ROE- 52W Range1.86 - 16.57 Perf YTD-53.97%
Dividend- P/FCF- EPS past 5Y-13.20% ROI- 52W High-82.14% Beta0.75
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low59.57% ATR0.32
Employees213 Current Ratio6.00 Sales Q/Q- Oper. Margin- RSI (14)55.75 Volatility22.01% 13.02%
OptionableYes Debt/Eq- EPS Q/Q-11.10% Profit Margin- Rel Volume1.27 Prev Close3.18
ShortableYes LT Debt/Eq- EarningsMay 10 AMC Payout- Avg Volume1.11M Price2.96
Recom2.20 SMA2025.97% SMA50-0.93% SMA200-53.81% Volume1,386,382 Change-6.92%
Jun-08-22Downgrade BofA Securities Buy → Neutral $12 → $4
Oct-08-21Downgrade JP Morgan Neutral → Underweight
Oct-01-21Downgrade Wedbush Neutral → Underperform
Oct-01-21Downgrade Maxim Group Buy → Hold
Sep-27-21Initiated JP Morgan Neutral $15
Feb-01-21Initiated UBS Buy $25
Oct-20-20Initiated BofA Securities Buy $21
Aug-21-20Reiterated H.C. Wainwright Buy $34 → $32
Aug-14-20Reiterated Maxim Group Buy $25 → $20
May-06-19Initiated Cantor Fitzgerald Overweight $26
Jul-12-18Initiated Seaport Global Securities Buy $30
Mar-23-18Downgrade Wedbush Outperform → Neutral $47 → $19
Mar-05-18Downgrade Needham Buy → Hold
Nov-08-17Initiated H.C. Wainwright Buy $30
May-11-17Downgrade Cantor Fitzgerald Buy → Neutral $21 → $15
Mar-17-17Reiterated Needham Buy $24 → $22
Mar-17-17Reiterated Maxim Group Buy $19 → $22
Nov-16-16Reiterated Wedbush Outperform $56 → $47
Nov-10-16Reiterated Needham Buy $28 → $24
Aug-10-16Reiterated Maxim Group Buy $30 → $19
Jun-15-22 08:00AM  
May-10-22 04:02PM  
May-04-22 08:30AM  
Apr-20-22 08:45AM  
Mar-01-22 04:02PM  
08:59AM  
Feb-28-22 08:34AM  
Feb-24-22 07:00AM  
Feb-03-22 09:38AM  
Jan-20-22 06:54AM  
Jan-19-22 05:52PM  
Dec-30-21 05:11PM  
Dec-23-21 09:10AM  
Dec-20-21 09:30AM  
Dec-15-21 11:34AM  
Dec-03-21 08:17PM  
Dec-02-21 08:22PM  
07:30AM  
05:58AM  
Nov-30-21 07:42AM  
Nov-09-21 06:25PM  
04:02PM  
Nov-05-21 04:45PM  
08:40AM  
08:30AM  
Nov-04-21 10:53AM  
08:30AM  
Nov-01-21 04:35PM  
03:01PM  
Oct-31-21 06:19AM  
Oct-26-21 03:15PM  
Oct-21-21 10:00AM  
Oct-20-21 08:31AM  
Oct-18-21 05:39PM  
12:24PM  
06:30AM  
Oct-15-21 09:45PM  
Oct-13-21 06:40PM  
04:35PM  
Oct-11-21 03:50PM  
Oct-07-21 10:30PM  
09:45PM  
12:16PM  
Oct-06-21 04:00PM  
Oct-05-21 06:32PM  
04:51PM  
10:10AM  
Oct-04-21 03:11PM  
01:11PM  
Oct-03-21 08:51PM  
Oct-01-21 05:02PM  
04:05PM  
12:47PM  
12:41PM  
12:11PM  
08:55AM  
08:32AM  
Sep-30-21 08:36PM  
Aug-09-21 05:35PM  
04:02PM  
Aug-03-21 08:30AM  
Aug-02-21 03:01PM  
08:24AM  
Jun-14-21 12:45PM  
08:30AM  
Jun-10-21 03:53PM  
08:45AM  
Jun-09-21 05:00PM  
08:45AM  
Jun-07-21 10:39PM  
12:39PM  
Jun-05-21 08:01PM  
Jun-02-21 10:15PM  
Jun-01-21 05:05AM  
May-31-21 05:16PM  
May-29-21 10:29PM  
May-28-21 12:00PM  
08:45AM  
May-27-21 10:08PM  
02:37PM  
May-26-21 09:13AM  
May-22-21 10:48PM  
May-21-21 09:55AM  
May-20-21 02:40PM  
08:45AM  
May-13-21 08:30AM  
May-10-21 05:55PM  
04:02PM  
02:30PM  
May-05-21 08:45AM  
May-04-21 05:45AM  
05:15AM  
Mar-23-21 08:45AM  
Mar-01-21 05:25PM  
04:18PM  
04:02PM  
02:30PM  
Feb-25-21 09:37AM  
Feb-03-21 05:30AM  
Jan-26-21 08:45AM  
Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS); and Phase II clinical trial to treat COVID-19. Its clinical programs also consist of PPAR? (OMS405) that is in Phase II to treat opioid and nicotine addiction; PDE7 (OMS527), which is in Phase I trial for treating addiction and compulsive disorders, and movement disorders; and MASP-3 (OMS906) that is in Phase I trial for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders. The company's preclinical programs comprise MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; longer-acting second generation antibody targeting MASP-2; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Its preclinical programs also include GPR174 Inhibitors and Chimeric Antigen Receptor (CAR) T-Cell and Adoptive T-Cell Therapies for various cancers; and G protein-coupled receptor targets for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HANISH ARNOLD CDirectorSep 08Option Exercise9.4410,00094,40010,000Sep 09 05:19 PM